Back to Peptide Library
Dual GLP-1 / GIP Agonist

Tirzepatide

39-Amino-Acid Dual Incretin Agonist • Once-Weekly Dosing

Tirzepatide is a long-acting dual GLP-1 and GIP receptor agonist used for type 2 diabetes and chronic weight management. It reduces appetite, slows gastric emptying, improves glucose-dependent insulin release, and produces substantial weight loss with extensive human clinical-trial evidence.

Weight Loss Appetite Control Glucose Regulation Metabolic Health
Protocol Snapshot

Quick reference before the deep dive

Verified Vendors
Tirzepatide
Peptide Protocols Tirzepatide product
Compare Verified Vendors
  • Current price and availability
  • Price per mg and vial-size comparison
  • Testing and fulfillment details
Compare
View Price Index
Starting Dose
2.5mg
Once weekly for the first four weeks.
Maximum Dose
15mg
Once weekly after gradual titration.
Frequency
Once Weekly
Use the same day each week.
Route
Subcutaneous Injection
Abdomen, thigh, or upper arm.
Peptide Grade
GradeA
Large trials, regulatory approval, and substantial real-world effectiveness establish a strong benefit profile, with gastrointestinal effects and lean-mass considerations requiring attention.
Research Community Safety
Foundation

Research context, mechanisms, and practical use cases

What Is Tirzepatide?

Tirzepatide is a 39-amino-acid synthetic peptide that activates both glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors. It is based on the native GIP sequence and modified with a C20 fatty diacid chain that promotes albumin binding and extends its half-life to approximately five days.

It is FDA approved as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management. Zepbound is also approved for moderate-to-severe obstructive sleep apnea in adults with obesity.

The dual mechanism separates tirzepatide from single-receptor GLP-1 agonists. GLP-1 activity primarily suppresses appetite, slows gastric emptying, and improves glucose regulation, while GIP activity adds insulinotropic effects and may improve nutrient partitioning and overall tolerability.

Tirzepatide Benefits

Substantial Weight Loss

In SURMOUNT-1, mean weight reduction reached 15.0% at 5mg, 19.5% at 10mg, and 20.9% at 15mg over 72 weeks.

Compared with Semaglutide

In SURMOUNT-5, maximum-tolerated tirzepatide produced 20.2% mean weight reduction versus 13.7% with semaglutide at 72 weeks.

Body Composition

A SURMOUNT-1 DEXA analysis found that approximately 75% of weight lost was fat mass and 25% was lean mass.

Blood Sugar Control

SURPASS trials reported HbA1c reductions of up to approximately 2.3 percentage points, with stronger results than semaglutide 1mg in SURPASS-2.

Liver Fat & MASH

In the phase 2 SYNERGY-NASH trial, MASH resolution without worsening fibrosis occurred in 44%–62% of tirzepatide-treated participants versus 10% with placebo.

Sleep Apnea

In SURMOUNT-OSA, mean apnea-hypopnea index changes were −25.3 and −29.3 events per hour with tirzepatide versus −5.3 and −5.5 with placebo.

Protocol Planning

Dosing, cycling, and preparation

Tirzepatide Dosing Protocol

FDA labeling starts tirzepatide at 2.5mg once weekly for four weeks, then moves to 5mg. Further increases are optional and should occur only in 2.5mg steps after at least four weeks at the current dose.

Label-Based Titration

Weeks 1–4
2.5mg once weekly for treatment initiation
Week 5+
5mg once weekly
Further Increases
Add 2.5mg only after at least 4 weeks at the current dose
Dose Selection
Base maintenance dose on response and tolerability
Maximum
15mg once weekly

Maintenance & Timing

Weight Management
5mg, 10mg, or 15mg once weekly
OSA
10mg or 15mg once weekly
Route
Subcutaneous injection
Timing
Same day weekly, any time, with or without food
Missed Dose
Take within 4 days; otherwise skip and resume the regular schedule
Lowest Effective Maintenance Dose

Not everyone needs 15mg. The label directs maintenance-dose selection by treatment response and tolerability, so escalation should not be automatic when a lower maintenance dose is working.

What to Expect

Appetite suppression often begins during the first month. Weight loss commonly becomes more consistent from 5mg upward, with the strongest effects occurring during the first six to twelve months.

Tirzepatide Reconstitution

Mixing Details

Vial Size
10mg
Diluent
2mL bacteriostatic water
Concentration
5mg/mL
Storage
Refrigerate after reconstitution
Reconstitution Calculator

Syringe Conversion

Per Unit
50mcg
500mcg
10 units
1mg
20 units
2.5mg
50 units
5mg
100 units
Anecdotal Data Points

Community-reported outcomes and recurring patterns

Self-reported anecdotal experiences aggregated from public & private peptide community discussions and anonymous peptideprotocols.app user reports. This information does not carry the same weight as published research.

Positive Reports

  • Food noise and constant background thinking about food often decrease substantially.
  • Many users report meaningful early weight loss, though the pace varies with dose, starting weight, nutrition, and adherence.
  • Appetite suppression usually becomes more pronounced between 5mg and 7.5mg.
  • Users who prioritize protein and resistance training report better strength and body-composition outcomes.
  • Some report improved energy as glucose control and other metabolic markers improve.
  • Lower doses remain effective for some people, reducing the need to escalate rapidly.

Negative Reports

  • Nausea, constipation, diarrhea, fatigue, and sulfur burps are commonly reported during titration.
  • Rapid appetite suppression can make it difficult to consume enough protein and calories.
  • Plateaus often occur after several months and do not always require a dose increase.
Stacking & Synergy

Potential Tirzepatide pairings and tracking context

Tirzepatide Stacking & Synergy

Resistance Training + Protein

The most important pairing for preserving strength and lean mass during substantial weight loss.

Tirzepatide + GH Peptides

Sometimes combined for body-composition goals and muscle preservation.

Other Tirzepatide or GLP-1 Products

Do not combine with another tirzepatide product or GLP-1 receptor agonist; FDA labeling does not recommend coadministration.

Insulin or Sulfonylureas

These combinations can increase hypoglycemia risk and may require supervised dose adjustment.

Free with login

Track in Journal

Compare weekly dosing with appetite, body composition, and GI tolerance.

  • Dose, injection day, and weeks at dose.
  • Weight, waist, appetite, and food noise.
  • Nausea, bowel habits, and hydration.
  • Protein intake, strength, and training.
Start Tracking
Safety Notes

Side effects, contraindications, and precautions

Tirzepatide Side Effects

Gastrointestinal effects are the most common and usually occur during dose escalation. Slow titration and smaller meals improve tolerability for many people.

Seek medical care for severe or persistent abdominal pain, repeated vomiting, inability to keep fluids down, jaundice, severe constipation with abdominal distention, or symptoms of an allergic reaction.
In Published Research
  • Common: nausea, diarrhea, vomiting, constipation, decreased appetite, abdominal discomfort, and fatigue.
  • Less common: reflux, belching, dizziness, injection-site reactions, and hair loss associated with rapid weight loss.
  • Important risks include gallbladder disease, delayed gastric emptying, dehydration-related kidney injury, and possible pancreatitis.
What Users Report
  • Nausea and constipation are most often reported during the first one to two weeks at a new dose.
  • Sulfur burps, reflux, fatigue, insomnia, and difficulty eating enough protein are common complaints.
  • Rapid or poorly supported weight loss may lead to reduced strength, hair shedding, and a “skinny-fat” appearance.

Tirzepatide Contraindications and Precautions

Do Not Use If You Have

  • A personal or family history of medullary thyroid carcinoma.
  • Multiple Endocrine Neoplasia syndrome type 2.
  • Known hypersensitivity to tirzepatide or formulation ingredients.
  • Pregnancy. Tirzepatide is not appropriate for weight loss during pregnancy.

Use Caution With

  • A history of pancreatitis, gallstones, gallbladder disease, or severe gastrointestinal disease.
  • Gastroparesis or persistent delayed gastric emptying.
  • Kidney disease, especially if vomiting or diarrhea may cause dehydration.
  • Diabetic retinopathy or rapidly improving blood glucose.
  • Upcoming surgery or anesthesia because delayed gastric emptying may increase aspiration risk.

Drug Interactions

Insulin and sulfonylureas can increase hypoglycemia risk when combined with tirzepatide. Delayed gastric emptying may affect oral medication absorption. People using oral hormonal contraceptives should follow label guidance to use a non-oral method or add a barrier method for 4 weeks after starting tirzepatide and for 4 weeks after each dose increase.

Monitoring

Monitor body weight, waist measurement, appetite, gastrointestinal tolerance, hydration, glucose, HbA1c when relevant, kidney function when clinically indicated, gallbladder symptoms, and lean-mass preservation.

Regulatory Status

Tirzepatide is FDA approved in branded formulations for type 2 diabetes, chronic weight management, and obstructive sleep apnea in eligible adults with obesity. Research-grade or compounded products are not automatically equivalent to approved commercial products.

FINAL VERDICT

Peptide Protocol's Opinionated Opinion

This is not medical advice. This editorial is our own opinion piece based off the experience of our own lab rats.

Tirzepatide is currently just behind Reta as the strongest weapon available for body recomposition and metabolic overhaul.


It’s not just another GLP-1—the dual GIP + GLP-1 action delivers superior appetite control, fat loss, and insulin sensitivity improvements with noticeably better muscle preservation than semaglutide. In the community, people are dropping serious body fat while holding onto more lean mass, especially when stacked intelligently with CJC/Ipa.


Tirzepatide is a game-changer for mid-life recomp if you respect the compound. Use it strategically—not blasting year-round—prioritize protein and resistance training, and pair it with supportive peptides to protect muscle and mitochondria.


It’s not a magic forever drug, but as a tool for getting leaner and healthier in a controlled window, Tirzepatide is elite. Hands down one of the highest-ROI peptides right now when run properly.